Meeting with Mr. Fabrice Le Vigoureux, LREM deputy for the 1st district of Calvados
April 23, 2019
This interview with Emmanuelle Huet-Mignaton, president of the association, aimed to present the AMAVEA association, whose headquarters are in the constituency of this deputy.
Subjects covered:
Presentation of the history of the problem of Meningiomes-Androcur and Progestifs link: Professor Froelich studies, ANSM reactions, Update of the notice by Bayer in 2011, CNAM study with results in the summer of 2018.
Creation of the association and its goals.
Discussion on the number of women concerned, on operations, the sequelae possible. The question of the consequences is always a recurring question, as with journalists.
Two cases are emerging, in summary:
- Either the person is operated, with more or less after -effects;
- Either it is not operated on and for two distinct reasons: either the operation is impossible, (location of the tumor which does not allow a sure neurosurgical gesture), or it is not necessary, because tumor too small, without symptoms, or or it is accessible by radiotherapy.
The term "Benin". Our tumors are not benign in the current sense of the term, they are as opposed to the term "cancer". A cardiac operation is not a cancer operation, and yet it is not nevertheless benign (see the problem of the mediator). Professor Froelich told the association that there was no hormone-dependent meningioma of Grade 3 (therefore cancer) to his knowledge.
The deputy informed me of his knowledge of the requests of certain deputies to the Minister of Health, and on which he is philosophically in agreement (in his words). The State does not have to replace the shortcomings of the pharmaceutical industry. Except, perhaps, if it is proven that the ANSM has its share of responsibility (and only its share, not all). The State is not an abstract entity, it is the community, so we do not have to charge, according to him, to the community of the shortcomings of an industrialist. This would be a very bad message to send to the pharmaceutical industry: keep not informing patients enough, and the state will take care of (badly, but will take it anyway). It turns out that it is very possible that people have already contacted their deputy, that he listened to them out of respect for their painful career, but did not have to follow in the Assembly, because he does not agree with the request for the creation of a special fund, without wanting to say it explicitly. Hence the lack of return which some people complain about.
Hence the need for the fundraising that Master Charles Joseph-Oudin does, essential for updating the responsibilities of the drug chain in this problem (as he did for the mediator and Dépakine): laboratory, ANSM, prescribing doctors.
We have also talked about the media and their role. Currently, many health "scandals" are in the spotlight: Dépakine for the 2nd generation, children without arms, Lévothyrox ..
People get tired of this continuous information of which they do not necessarily perceive what concerns him personally or not.
The contact has been good, from my point of view, and this deputy will remain open to our proposals, and will help us to the extent of his means.
This deputy has the responsibility within the Assembly. Standing committee:
- Finance, general economy and budget control (member)
- Judicial, international or extra-parliamentary functions: departmental commission provided for in article l. 2334-37 of the general code of local authorities (full member)
- Study and friendship groups:
Meeting with Mr. Fabrice Le Vigoureux, LREM deputy for the 1st district of Calvados
Find the other Amavea articles here
